Literature DB >> 30808680

Sustained Type I Interferon Reinforces NK Cell-Mediated Cancer Immunosurveillance during Chronic Virus Infection.

Ji Hoon Oh1, Myeong Joon Kim1, Seong Jin Choi2, Young Ho Ban1, Heung Kyu Lee3,4, Eui-Cheol Shin2, Kyung-Mi Lee5, Sang-Jun Ha6.   

Abstract

The importance of natural killer (NK) cells in the early immune response to viral or bacterial infection is well known. However, the phenotype, function, and physiologic role of NK cells during the late stage of persistent viral infection have not been extensively studied. Here, we characterized NK cells in mice persistently infected with lymphocytic choriomeningitis virus clone 13 and showed that in contrast to NK cells from acutely infected or uninfected mice, NK cells from chronically infected mice expressed a terminally differentiated phenotype, stronger cytotoxicity, and reduced inhibitory receptor expression. In an in vivo tumor model, chronically infected mice exhibited significantly delayed tumor progression in an NK cell-dependent manner. NK cells from chronically infected mice also expressed high STAT1, and blocking the type I interferon (IFN) receptor revealed that type I IFN signaling directly regulated NK cell cytotoxicity. Our findings indicate that sustained type I IFN signaling during chronic viral infection potentiates the cytolytic function of NK cells and contributes to NK cell-dependent host immune surveillance. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30808680     DOI: 10.1158/2326-6066.CIR-18-0403

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  12 in total

1.  Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Colby Stotesbury; Carolina R Melo-Silva; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

2.  Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer.

Authors:  Damien J Zanker; Katie L Owen; Nikola Baschuk; Alex J Spurling; Belinda S Parker
Journal:  Cancer Immunol Immunother       Date:  2021-01-15       Impact factor: 6.968

Review 3.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 4.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

5.  CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells.

Authors:  Songyi Park; Ji Hoon Oh; Dong Jin Park; Haiying Zhang; Minyoung Noh; Yeomyung Kim; Ye-Seul Kim; Hyejeong Kim; Young-Myeong Kim; Sang-Jun Ha; Young-Guen Kwon
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

6.  Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment.

Authors:  ZhiYu Zhao; Wei Liu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 7.  Modulation of Inflammation-Induced Tolerance in Cancer.

Authors:  Vladimir Rogovskii
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

8.  Lactate dehydrogenase-elevating virus enhances natural killer cell-mediated immunosurveillance of mouse mesothelioma development.

Authors:  Mohamed F Mandour; Pyone Pyone Soe; Catherine Uyttenhove; Jacques Van Snick; Etienne Marbaix; Jean-Paul Coutelier
Journal:  Infect Agent Cancer       Date:  2020-05-07       Impact factor: 2.965

Review 9.  Detection of immunogenic cell death and its relevance for cancer therapy.

Authors:  Jitka Fucikova; Oliver Kepp; Lenka Kasikova; Giulia Petroni; Takahiro Yamazaki; Peng Liu; Liwei Zhao; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Death Dis       Date:  2020-11-26       Impact factor: 8.469

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.